We use cookies for a better user experience. Read our Privacy Policy

I Agree

HER2 Antibodies Market

HER2 Antibodies Market (Type of Treatment Drugs - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab, and Everolimus) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

HER2 Antibodies Market - Snapshot

The growth of the global HER2 antibodies market is prophesized to be shaped by the rising demand for the antibodies worldwide. The market is gathering momentum from the augmented awareness about the rising prevalence of HER2 positive breast cancer. Various statistics reflect that the incidences of breast cancer has increased manifold over the last decade.

According to the World Health Organization (WHO), there are nearly around 200 different types of cancers in the world. Off all these, breast cancer has emerged as one of the most common types of cancer that has been plaguing women in recent times. Many pharmaceutical companies have engaged in extensive research and development activities in the light of such high prevalence of various types of cancers. Their purpose is to develop novel therapeutics to treat cancer.

Presence of Pipeline Drugs to Offer Hope to Cancer Patients

The demand within the global HER2 antibodies market has been spiraling in recent times. There is no one single cause for the occurrence of breast cancer. However, there are certain factors that are linked with the high prevalence of the disease and it includes the following

  • Obesity
  • late pregnancy
  • alcohol consumption
  • early-age menstruation

In the landscape of global healthcare, a number of associations for the treatment of cancer have come up. This has resulted in raising the awareness about the prevention and treatment of breast cancer. This factor, in turn, has added to the expansion of the global HER2 antibodies market in the years to come. Presence of a number of pipeline drugs offer beacon of hope to the cancer stricken persons. The healthcare industry has been pinning their hopes in these drugs to better the oncology field. Apart from that, change in lifestyle together with augmented consumption of alcohol and relentless smoking of cigarettes are likely to fuel growth of the global HER2 antibodies market in the years to come.

Global HER2 Antibodies Market: Snapshot

The demand in the global HER2 antibodies market is projected to increment at a robust CAGR of 8.6% during the forecast period of 2017 to 2025, primarily gaining from growing awareness regarding the prevalence of HER2 positive breast cancer. As per the figures provided by The American Cancer Society, 252,710 women were to be diagnosed with breast cancer in the U.S in 2017, with one in five females suffering from HER2 positive breast cancer. The global HER2 antibodies market is estimated to be worth US$ 21,669.1 mn by the end of the forecast period, i.e. 2025, considerably up from its evaluated worth of US$ 10,087.8 mn in 2016.

global her2 antibodies market

Trastuzumab Emerges as In-demand Therapeutic Drugs Type

Based on the type of therapeutic drugs, the global HER2 antibodies market has been segmented into five major classes, viz. Trastuzumab, Ado-trastuzumab emtansine, Lapatinib, Everolimus, and Pertuzumab. Trastuzumab (Herceptin) is the first approved in the U.S. in 1998, and remains the gold standard for HER2-postive breast cancer. In 2016 too, Trastuzumab accounted for the most substantial chunk of the market at 62.1% shares terms of revenue. However, Tykerb is likely to emerge as a significant threat given its oral bioavailability. Growth in incidence of breast cancer and rise in cost burden for its treatment can drive the market during forecast period. Trastuzumab account for the prominent share in the HER2 antibodies market. However due to the high cost of products the market for the HER2 breast cancer is restraining the market during the forecasted period. However the market for HER2 antibodies is experiencing entry of large number of new drugs in the market. Few have already arrived and other more promising drugs are on their way to launch in this market 

North America and Europe to Remain Most Lucrative Regions

Geographically, the HER2 antibodies market has been bifurcated into the regions of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2016, North America accounted for the most prominent share of 42.7% of the global HER2 antibodies market, followed by Europe with less than a quarter of the global demand. This strong demand from the two regions is attributed to well-established health care infrastructure coupled with awareness of population regarding the treatment of HER2 breast cancer. The market in North America and Europe is expected to dwindle during the forecast period due to maximum top selling brands in these regions will be encountering by their exclusivity and patent expiry.

Revenue-wise, U.S. is the most profitable country-wide market for HER2 antibodies in North America while Rest of Europe and Germany market leading the Europe region. Asia Pacific may provide an attractive market for the HER2 antibodies because of increasing per capita income and increasing healthcare facilities and awareness regarding HER2 breast cancer. Besides Asia Pacific, Latin America region too is focusing on increasing the diagnostic rate of cancer and types of cancer, which will be driving the market during forecast period. Governments and non-profit organizations in the region are striving to spread awareness and control the increasing incidence rate of breast cancer. The incidence of cancer in Middle East & Africa is currently lower than that in countries such as the U.S. and the U.K. However, it is expected to rise rapidly compared to other regions in the next decade.

Novartis AG, Genentech Inc., Abnova Corporation, Pfizer, Inc., InvivoGen, Biocon Limited, Bio-Techne, and Celltrion, Inc. are some of the key companies currently operating in the global HER2 antibodies market.

The global HER2 Antibodies market is segmented as follows:

by Type of Treatment Drugs

  • Trastuzumab
  • Lapatinib 
  • Ado-trastuzumab emtansine 
  • Pertuzumab   
  • Everolimus  

by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa
HER2 Antibodies Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global HER2 Antibodies Market

4. Market Overview
      4.1. Introduction
      4.2. Overview
      4.3. Key Market Indicators
      4.4. Market Dynamics
              4.4.1. Drivers
              4.4.2. Restraints 
              4.4.3. Opportunities
              4.4.4. Trends
      4.5. Global HER2 Antibodies Market Analysis and Forecasts, 2015–2025
              4.5.1. Market Revenue Projections (US$ Mn)
      4.6. Porter’s Five Force Analysis
      4.7. Market Outlook

5. Global HER2 Antibodies Market, Analysis and Forecasts, By Type of Treatment Drugs
      5.1. Introduction & Definition
      5.2. Key Findings / Developments      
      5.3. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              5.3.1. Trastuzumab 
              5.3.2. Lapatinib 
              5.3.3. Ado-trastuzumab emtansine
              5.3.4. Pertuzumab 
              5.3.5. Everolimus 

6. Global HER2 Antibodies Market Analysis and Forecasts, By Region
      6.1. Key Findings
      6.2. Market Value Forecast by Region
              6.2.1. North America 
              6.2.2. Europe 
              6.2.3. Asia Pacific 
              6.2.4. Latin America 
              6.2.5. Middle East and Africa 
      6.3. Market Attractiveness by Country/Region

7. North America HER2 Antibodies Market, Analysis and Forecast
      7.1. Introduction
              7.1.1. Key Findings
              7.1.2. Policies and Regulations
              7.1.3. Key Trends
      7.2. Market Value Forecast by Country, 2015–2025
              7.2.1. U.S.
              7.2.2. Canada
      7.3. Market Attractiveness by Country      
      7.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              7.4.1. Trastuzumab 
              7.4.2. Lapatinib 
              7.4.3. Ado-trastuzumab emtansine
              7.4.4. Pertuzumab 
              7.4.5. Everolimus 
      7.5. Market Attractiveness by Type of Treatment Drugs

8. Europe HER2 Antibodies Market, Analysis and Forecast
      8.1. Introduction
              8.1.1. Key Findings
              8.1.2. Policies and Regulations
              8.1.3. Key Trends
      8.2. Market Value Forecast by Country, 2015–2025
              8.2.1. U.K.
              8.2.2. Germany
              8.2.3. France
              8.2.4. Italy
              8.2.5. Spain
              8.2.6. Rest of Europe
      8.3. Market Attractiveness by Country
      8.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              8.4.1. Trastuzumab 
              8.4.2. Lapatinib 
              8.4.3. Ado-trastuzumab emtansine
              8.4.4. Pertuzumab 
              8.4.5. Everolimus 
      8.5. Market Attractiveness by Type of Treatment Drugs

9. Asia Pacific HER2 Antibodies Market, Analysis and Forecast
      9.1. Introduction
              9.1.1. Key Findings
              9.1.2. Policies and Regulations
              9.1.3. Key Trends
      9.2. Market Value Forecast by Country, 2015–2025
              9.2.1. Japan
              9.2.2. China
              9.2.3. India
              9.2.4. Australia & New Zealand
              9.2.5. Rest of Asia Pacific
      9.3. Market Attractiveness by Country
      9.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              9.4.1. Trastuzumab 
              9.4.2. Lapatinib 
              9.4.3. Ado-trastuzumab emtansine
              9.4.4. Pertuzumab 
              9.4.5. Everolimus 
      9.5. Market Attractiveness by Type of Treatment Drugs

10. Latin America HER2 Antibodies Market, Analysis and Forecast
      10.1. Introduction
              10.1.1. Key Findings
              10.1.2. Policies and Regulations
              10.1.3. Key Trends
      10.2. Market Value Forecast by Country, 2015–2025
              10.2.1. Brazil
              10.2.2. Mexico
              10.2.3. Rest of LATAM
      10.3. Market Attractiveness by Country
      10.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              10.4.1. Trastuzumab 
              10.4.2. Lapatinib 
              10.4.3. Ado-trastuzumab emtansine
              10.4.4. Pertuzumab 
              10.4.5. Everolimus 
      10.5. Market Attractiveness by Type of Treatment Drugs

11. Middle East & Africa HER2 Antibodies Market, Analysis and Forecast
      11.1. Introduction
              11.1.1. Key Findings
              11.1.2. Policies and Regulations
              11.1.3. Key Trends
      11.2. Market Value Forecast by Country, 2015–2025
              11.2.1. Saudi Arabia
              11.2.2. South Africa
              11.2.3. Rest of MEA
      11.3. Market Attractiveness by Country
      11.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              11.4.1. Trastuzumab 
              11.4.2. Lapatinib 
              11.4.3. Ado-trastuzumab emtansine
              11.4.4. Pertuzumab 
              11.4.5. Everolimus 
      11.5. Market Attractiveness by Type of Treatment Drugs

12. Pipeline Analysis
      12.1. Pipeline Snapshot for HER2 Antibodies Market

13. Competition Landscape
      13.1. Heat Map Analysis by Company (2016)
      13.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
              13.2.1. Novartis AG
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.2. Pfizer, Inc. 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.3. Genentech Inc. (F. Hoffmann-La Roche Ltd.)
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.4. Abnova Corporation 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.5. InvivoGen 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.6. Celltrion, Inc. 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.7. Biocon Limited 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.8. Bio-Techne (Novus Biologicals, LLC)
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 

List of Tables

Table 01: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 02: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 03: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 04: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 05: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 06: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 07: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 08: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 09: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 10: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 11: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 12: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025

List of Figures

Figure 01: HER2 Antibodies Market, by Type of Treatment Drugs, Market Size (US$ Mn), 2016 (A)
Figure 02: HER2 antibodies market revenue (%), by top three drugs, 2016 (A)
Figure 03: Executive Summary (2/3)
Figure 04: Executive Summary (3/3)
Figure 05: Opportunity Map, 2017
Figure 06: Key Industry Developments
Figure 07: Drivers and Restraints Snapshot (1/1)
Figure 08: Global HER2 Antibodies Market Size (US$ Mn) Forecast, 2015–2025
Figure 09: Porter’s Five Forces Analysis (1/2)
Figure 10: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs (2016)
Figure 11: Global HER2 Antibodies Market Value Share, by Region (2016)
Figure 12: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 13: Global HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 14: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Trastuzumab, 2015–2025
Figure 15: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lapatinib, 2015–2025
Figure 16: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Ado-trastuzumab Emtansine, 2015–2025
Figure 17: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pertuzumab, 2015–2025
Figure 18: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Everolimus, 2015–2025
Figure 19: Global Market Scenario
Figure 20: Global HER2 Antibodies Market Value Share, by Region, 2017 and 2025 
Figure 21: Global HER2 Antibodies Market Attractiveness, by Region, 2017–2025
Figure 22: North America HER2 Antibodies Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2015–2025
Figure 23: North America HER2 Antibodies Market Attractiveness Analysis, by Country
Figure 24: North America HER2 Antibodies Market Value Share Analysis, by Country, 2017 and 2025
Figure 25: North America HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 26: North America HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 27: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2015–2025
Figure 28: Europe HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
Figure 29: Europe Market Value Share Analysis, by Country, 2017 and 2025
Figure 30: Europe HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 31: Europe HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 32: Asia Pacific HER2 Antibodies Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
Figure 33: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Country. 2017-2025
Figure 34: Asia Pacific Market Value Share Analysis, by Country, 2017 and 2025
Figure 35: Asia Pacific HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 36: Asia Pacific HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 37: Latin America HER2 Antibodies Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
Figure 38: Latin America HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
Figure 39: Latin America Market Value Share Analysis, by Country, 2017 and 2025
Figure 40: Latin America HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 41: Latin America HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 42: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) and
Figure 43: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
Figure 44: Middle East & Africa Market Value Share Analysis, by Country, 2017 and 2025
Figure 45: Middle East & Africa HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 46: Middle East & Africa HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 47: Pipeline Snapshot of HER2 Antibodies Market (1/2)
Figure 48: Pipeline Snapshot of HER2 Antibodies Market (2/2)
Figure 49: Global HER2 Antibodies Market Heat Map Analysis by Company (2016)
Figure 50: Novartis AG Breakdown of Net Sales, by Region (2016)
Figure 51: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 52: Pfizer, Inc. Breakdown of Net Sales, by Region (2016)
Figure 53: Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 54: Genentech Inc. Breakdown of Net Sales, by Segment, 2016
Figure 55: Genentech Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 56: Abnova Corporation Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 57: Celltrion, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2015
Figure 58: Biocon Limited Breakdown of Net Sales, by Business Segments, 2016
Figure 59: Biocon Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 60: Bio-Techne Breakdown of Net Sales, by Business Segment, 2016
Figure 61: Bio-Techne Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

391

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved